DDInter1471 DDInter1376
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pindolol {u} (Compound) resembles {v} (Compound) Betaxolol
Pindolol {u} (Compound) resembles {v} (Compound) Atenolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Pindolol {u} (Compound) treats {v} (Disease) hypertension
Pindolol {u} (Compound) binds {v} (Gene) HTR1A
Pindolol {u} (Compound) upregulates {v} (Gene) TBP
Pindolol {u} (Compound) downregulates {v} (Gene) PTK2B
Pindolol {u} (Compound) causes {v} (Side Effect) Dyspepsia
Pindolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Pindolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Pindolol (Compound) resembles Betaxolol (Compound)
Pindolol (Compound) resembles Atenolol (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Pindolol (Compound) treats hypertension (Disease)
Pindolol (Compound) binds HTR1A (Gene)
Pindolol (Compound) upregulates TBP (Gene)
Pindolol (Compound) downregulates PTK2B (Gene)
Pindolol (Compound) causes Dyspepsia (Side Effect)
Pindolol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Pindolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate